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Abstract
Pharmaceutical drugs—prescription drugs, not over-the-counter drugs—have prices that 
are negotiated between pharmaceutical companies and National Ministry of Health or 
national agency for medicines or national health insurers in every country. Prescription 
drug expenditures have increased every country’s healthcare costs. Medication adher-
ence (defined as not obtained refills of prescriptions or suboptimal dosing of prescribed 
drugs) is a growing concern to physicians and healthcare systems because of the multiple 
evidence of noncompliance among patients and correlated adverse outcomes. A patient 
is considered adherent if he/she takes 80% of his/her prescribed medicine(s). Different 
studies showed that patients do not take their prescribed medicines about half the time. 
Financial losses due to poor adherence are the result of unnecessary time-consuming 
work and costs for potential harm to patients. Hospitalization rates are reduced at higher 
levels of medication adherence. There are two types of financial losses due to poor 
treatment adherence: medical costs (measured by hospitalization risk) and drugs costs 
(without patient copayments). This financial loss analysis underlines the promotion of 
medication adherence by the patients.
Keywords: adherence, drugs, costs, persistence, concordance, compliance
1. Introduction
Chronic diseases such as diabetes, stroke, arthritis, and heart diseases are the main cause of 
disability and death throughout the world. More than 40% of the people suffer in their adult 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
life from a chronic disease, and approximately 20% are hospitalized because of it. Another 
perspective is that they are costly, but in many cases preventable. The main cause is usually 
lifestyle choices that are hard to change; eating foods that are low in fats, becoming more physi-
cally active, and avoiding tobacco can help from developing high-risk conditions and diseases.
Patients with multiple chronic diseases struggle with great challenges on their daily lives; 
also, they experience poor health outcomes and will tend to use health national services more 
than patients with single chronic disease. Not respecting treatment prescriptions have both 
personal health impact and health economics consequences. These people are regarded as the 
highest cost patient populations in the healthcare system [1], with a poor adherence to treat-
ment and medical advices. Worldwide, experts are examining the situation in which health 
care can be better organized to meet the needs of every patient. It was demonstrated that 
every dollar spent for improving adherence saves seven dollars in total healthcare costs [2, 3].
The absence of appropriate clinical practice guidelines for patients with multiple chronic 
diseases is a huge problem, which healthcare providers contend. Furthermore, patient-
centered care needs to be supported through the transition of a more oriented approach to 
help patients prioritize their condition.
Moreover, not taking the required medication prescribed can have both personal health impact 
and health economics consequences. Recently, patients have shown increased interest in their 
own healthcare possibilities, raising the overall rate of adherence to treatment. However, the 
cost-effectiveness is still a parameter that is often ignored when a medical expert chooses to 
treat different kinds of conditions. Adherence is defined as “persistence in a practice,” so this 
definition emphasizes the routine that people with chronic disease ideally engage in when 
taking prescription medication [4].
The term first used was “compliance.” Charavel et al. [5] described this concept like physi-
cian alone makes the treatment decision, while the passive and dependent patient is obliged 
to comply with it. But the patient is not so silent and the term “adherence” is more used, the 
patient is more engaged in taking prescription medication.
Adherence cannot be defined as an “all or nothing” response in which the patient either fol-
lows the prescriber’s instruction to the letter (adherence) or deviates from it in some way 
(nonadherence) [6]. A patient is considered adherent if he/she takes 80% of his/her prescribed 
medicine(s). In the current era of free and easy access to information, with a higher educa-
tional level across the population, the concept of “concordance” seems to win for some dis-
eases, when the patient want to defer decisions entirely to their health professionals or family 
members. Some patients prefer a collaborative role, whereas others prefer a passive role.
The most common chronic diseases that have a low adherence rate to treatment are asthma, 
diabetes, heart disease, obesity, rheumatic diseases, eating disorders, chronic obstructive pul-
monary disease (COPD), and psychotic disorders.
The estimated rate of adherence is only half of the percentage of the patients with chronic dis-
eases. Ten days after a new prescription has been filled [7], another quarter of the patients have 
missed one dose of the medication (intentionally or unintentionally). This kind of behavior 
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causes concern among the medical experts, so they have to make strong decisions in order to 
make the treatment more functional for every patient.
The top three therapy classes used for chronic diseases are inflammatory conditions, multiple 
sclerosis, and cancer. These three account more than a half of the total spend for all spe-
cialty medications. The new trend is that patients often shift from using brand medications 
to lower cost generics; as they do this, the copayments decline and also the adherence drops 
significantly.
The medications used to treat diabetes, high blood cholesterol and high blood pressure, ulcer, 
and asthma were the most expensive traditional therapy class. Also these classes had the 
minimum nonadherence rate (between 20 and 35%). In the case of ulcer disease, it is more 
likely for aged people to be more adherent to the treatment. Asthma is another case of strong 
nonadherence cases for the pediatric patients.
Correct understanding of barriers for adherence and strategies used can help physicians edu-
cate their patients more appropriately, reducing the risk of nonadherence and achieving an 
improvement of the healthcare system [8].
A lot of studies were done to estimate the costs related to nonadherence to drug therapy 
in developed countries, making distinctions between primary nonadherence (prescriptions 
not being filled by the patient) and secondary nonadherence (medication not being taken as 
prescribed). World Health Organization (WHO) published in 2003 a report of poor adherence 
to treatment of chronic diseases in which developing countries were found to have a higher 
rate of nonadherence than the 50% average of nonadherence to long-term therapy for chronic 
diseases in developed countries [9].
Mills et al. [10] examined both developed and developing nations in a systematic review of 
adherence and reported the same important barriers (fear of disclosure, substance abuse, for-
getfulness, suspicions of treatment, too complicated regimens, too many pills, and decreased 
quality of life), with some facilitators reported by patients in developed nation (having a sense 
of self-worth, accepting their disease, understanding the need for strict adherence, making 
use of reminder tools, and having a simple regimen).
2. Pharmacoeconomic tools
An economic evaluation of adherence consists in assessing the outcomes and costs of inter-
vention designed to improve health. It is like we evaluate a new intervention when the new 
one is not compared with usual health care, for example the standard intervention, but with 
no intervention at all. The incremental cost-effectiveness ratio (ICR) is the difference in costs 
(C) between the drug and no drug divided by the difference in effects (E) between the drug 
and no drug.
  ICR =   C drug −  C no drug  _____________
 E 
drug
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A summary of the characteristics of these types of economic evaluation is described in Table 1.
The most used techniques are cost-effectiveness analysis (CEA) and cost-utility analysis 
(CUA). A budget impact analysis (BIA) might be added to the economic evaluation.
2.1. Cost-effectiveness analysis
A cost-effectiveness analysis of adherence shows effects in naturally occurring units, such as 
death, illnesses or burns prevented, and the costs in monetary units (Euros, Dollars, etc.). We 
can use this type of analysis because it provides information about the relative efficiency of 
alternative interventions that serve the same goal, what happened if the adherence is smaller 
comparative with a higher value. A cost-effective analysis must contain effect outcomes and 
the costs for the different values of adherence and should compare them. Cost-effectiveness 
analysis is the simplest type of economic evaluation to explain the differences in outcomes.
Measuring benefits in natural units is the main advantage and focusing on a single outcome—
adherence—could be considered a disadvantage.
2.2. Cost-utility analysis
Cost-utility analysis evaluates the difference in costs relative to the difference in quality 
adjusted life years (QALYs). Both types of effects—on the life expectancy and on quality 
of life—are used to justify the costs. QALYs are represented by the number of gained life 
Methods Costs Effects Evaluation question
Cost-effectiveness analysis 
(CEA)
Monetary units Natural units (life-years gained, 
burns prevented, etc.)
Comparisons of 
interventions with same 
objective
Cost-utility analysis (CUA) Monetary units Utility and QALY (quality-adjusted 
life-year) or DALY (disability-
adjusted life-year)
Comparison of 








Monetary units The effects are not measured, since 
they are considered to be equal
Least-cost comparisons of 
programs with the same 
outcome
Table 1. Characteristics of the four types of pharmacoeconomic evaluations [11].
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years corrected for quality of life. The QALY is the standard outcome measure existed in 
health economic evaluations, but there are some countries (Germany, Spain, and USA) that 
decided to ban the use of QALY in Health Technologies Assessment (HTA), after consider-
ing that QALY is methodologically and ethically not robust for health decision making. It 
is based on the use of subjective parameters, which are less robust than the chemical and 
biochemical parameters.
QALYs are determined with the aid of generic measurement instruments like EQ-5D [12], 
SF-6D (Short Form 6D), DCE (discrete-choice experiment), or MCDA (multi-criteria decision 
analysis). Another examples of generic instruments are Nottingham Health Profile (NHP), 
quality of well-being scale (QWB), sickness impact profile (SIP), and Health Utilities Index 
(HUI) Mark III.
EQ-5D is one of the most commonly used questionnaires to measure health-related qual-
ity of life (HRQOL). It consists of a questionnaire about five directions of current health 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual 
analogue scale (EQ-VAS). It was developed for adults, but a new version has been recently 
developed for children aged 8–18 years old (EQ-5D-Y) and the five dimensions are: walking 
about, look-after myself, doing usual activities, having pain or discomfort, feeling worried, 
sad or unhappy.
Nottingham Health Profile (NHP) [13] includes two parts: Part I about distress within the 
following domains: emotions, sleep, social isolation, energy, pain, and mobility and Part II 
about health-related problems within the domains: occupation, housework, social life, home 
life, sex life, hobbies, and holidays.
Quality of Well-Being Scale (QWB) [14] includes questions about symptoms/problems, mobil-
ity, physical activity, and social activity.
Sickness impact profile (SIP) [15] includes questions about sleep/rest, eating, work, ambula-
tion, mobility, communication, home management, recreation and pastimes, body care and 
movement, alertness behavior, emotional behavior, and social interaction.
Health Utilities Index (HUI) Mark III [16] includes questions about vision, hearing, speech, 
ambulation, dexterity, cognition, pain and discomfort, and emotion (Figure 1).
The complexity of assessing outcomes in cost-utility analysis is a disadvantage, even if this 
analysis can decide the best way of spending a given treatment budget or the healthcare bud-
get as a whole.
2.3. Cost-benefit analysis
Cost-benefit analysis evaluates the difference in costs relative to the difference in benefits, 
with the benefits expressed in monetary units. This is the only pharmacoeconomic analysis 
that could determine how much more or less of society’s resources could be allocated to pur-
suing increasing patient adherence.
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Figure 1. EQ-5D health questionnaire.
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Measuring benefits in monetary units is a disadvantage because it is a problem to valuate 
benefits, including death and disease, in money units.
2.4. Cost-minimization analysis
This analysis is performed when two health alternatives are equal, but few interventions are 
actually equally effective. Some evidence must support the assertion that outcomes are the 
same.
Cost-minimization analysis is not an appropriate method of analysis adherence costs.
In order to estimate costs, studies must include costs for hospitalization, outpatient ser-
vices, hospital stays, emergency care, clinical visits, laboratory tests, professional services, 
pharmaceuticals, and medical devices. Patients’ copayments and deductibles must not 
be included in costs assessment. Indirect costs (cost to society due to illness) and direct 
nonmedical costs (costs to the patient such as travel) could have a significant impact on 
total costs.
3. Adherence measuring
The concept of adherence or compliance can be measured in many different ways, includ-
ing multi-item questionnaire scales, individual questionnaire, independent observations from 
patients and physicians, electronic monitoring devices, etc.
Many methods have been utilized to collect data for measuring medication adherence. Some 
data collection techniques include directly observing patients consuming medications, moni-
toring through electronic pill dispensers, and measuring clinical outcomes, such as, serum 
drug concentration levels. Other methods include clinical data from clinical trials, administra-
tive claims data, electronic pharmacy databases, registries, patient and provider surveys, and 
paper medical records. There are several methods for measuring medication adherence using 
data obtained from these techniques that measure the time a patient has access to medica-
tion, including the medication possession ratio (MPR = number of days of medication sup-
plied within the refill interval/number of days in refill interval), proportion of days covered 
(PDC=total days all drugs available/days in follow-up period), missing days, time to discon-
tinuation, persistence rate, medication gaps, or self-reported questionnaires like Composite 
Adherence Score (CAS), Morisky Medication Adherence Scale (MMAS) with 4/8/9 questions, 
and Compliance Questionnaire for Rheumatology (CQR) with 5/19 questions.
3.1. Rheumatic diseases
In rheumatology clinics, Berry et al. [17] found nonadherence patients who were 
answering ‘no’ to the question “Have you taken medicine regularly as prescribed or 
directed?”, more common among new (28%) than follow-up patients (1%). Overall, the 
patients were more on nonsteroidal anti-inflammatory drug (NSAIDs) than on disease-
modifying antirheumatic drug (DMARDs), also the adherence was better for them, 
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according to the symptoms and directed dose. Another difference measured in adher-
ence is the cultural one, especially because of the economic impact of the treatment, 
that can lead to big cost problems. The follow-up adherence among patients with lupus 
depends on the medications prescribed. McElhone et al. [18] discussed that the perfect 
adherence rate is between 100% for treatment with azathioprine, 94% for oral steroids, 
and 68% for NSAIDs.
In the case of rheumatoid arthritis (RA), adherence is estimated at similar values. Researchers 
such as Neame and Hammond [19] found that 90% of the patients with RA are in fact taking 
their medication according to doctors’ recommendations. Adherence rate is also correlated 
with the type of medication that is prescribed. The overall adherence is approximately 70% 
for NSAIDs, 50% for sulfasalazine and 80% for methotrexate, according to Klerk et al. [20]. 
Viewing the results, the weekly treatment with methotrexate may facilitate the enhanced 
adherence rate. In addition, patients’ result are not as dependent on NSAIDs as it is thought, 
and this can be a good thing for the recent concerns about the cardiovascular risk associated 
with continuous usage of the high-dose drug.
3.2. Diabetes
The healthcare costs and the nonadherence to treatment for diabetes are both  problems that 
need to be resolved. The information that is available at this moment regarding patient’s 
adherence in diabetes is very poor. Studies have shown that adherence in diabetes is related 
more often to insulin (from 19 to 46%) [21], than to oral agents. The complications and the 
cost-effectiveness of antidiabetic drugs are a serious problem, according to the American 
Diabetes Association [22]. Inadequate use or poor adherence to insulin results in ketoacidosis 
that often requires hospitalization and more costs.
For people with diabetes, all-cause medical costs decrease as hypoglycemic drugs’ adherence 
increases.
Sokol et al. [2] demonstrated that costs and hospitalization risk for people with diabetes 
monotonically decreased as adherence to drug treatment increased (Table 2).
Even if drug cost is bigger and medical cost is smaller in the case of adherent patients (adher-
ence level>80), the total cost is the smallest. These savings probably reflect the effects of 
Adherence level Medical cost ($) Drug cost ($) Total cost ($) Hospitalization risk 
(%)
1–19 8812 55 8867 30
20–39 6959 165 7124 26
40–59 6237 285 6522 25
60–79 5887 404 6291 20
80–100 3808 763 4570 13
Table 2. Costs for people with diabetes.
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improved glycemic level on related diseases like microvascular disease or neuropathy, reduc-
ing the need for medical services.
Balkrishnan et al. [23] found that a 10% increase in medication possession ratios (MPRs) for an 
antidiabetic medication was associated with an 8.6% reduction in total annual healthcare costs.
Cobden et al. [36] used MPR to assess diabetic patients and found that MPR of 80% or greater 
was associated with significant reduction in all-cause healthcare costs. MPR of 68% was asso-
ciated with total mean costs of $8056, whereas an MPR of 59% had total mean costs of $8699.
Gilmer et al. [24] estimated that medical care costs increased significantly for each 1% increase 
in HbA1c (glycosylated hemoglobin) above 7%. For a person with an HbA1c value of 6%, suc-
cessive 1% increases in HbA1c resulted in cumulative increases in charges of almost 4, 10, 20, 
and 30%. For adults with diabetes and other diseases the costs are also increased. The most 
substantial cost increments occurred in individuals who had diabetes in combination with 
heart disease and hypertension: a 1% improvement in HbA1c level from 10 to 9% was associ-
ated with increasing in costs of $4116. The differences in costs are lower if the HbA1c value is 
smaller. If the patient isn’t adherent to the antidiabetic medicines, the increased HbA1c will 
rise the costs for healthcare system (Table 3).
Nonadherence to oral hypoglycemic medications may partly explain why only 43% of patients 
with diabetes mellitus have HbA1c below 7% level [21].
3.3. Pulmonary diseases (chronic obstructive pulmonary disease)
Chronic obstructive pulmonary disease (COPD) is a chronic limitation hat is usually progres-
sive and not reversible. The main treatment for this condition aims to reduce symptoms, pre-
vent exacerbations and delay the progression of the disease. Although medication has not been 
shown to modify the long-term of lung disease, various medications are available to prevent and 
control patients’ symptoms, and improve health. Patient adherence to medication for COPD is 
very poor compared with rates for medicines and other long-terms conditions. Nonadherence 
to medication is a risk factor for morbidity, hospital admission and increased mortality.
Zaniolo et al. [27] made a budget impact study to demonstrate the implications of the adher-
ence to patients with chronic obstructive pulmonary diseases. The target population that they 
Changes in HbA1c levels
10–9% 9–8% 8–7% 7–6%
Patients with diabetes, heart disease, and 
hypertension
$4116 $3090 $2237 $1504
Patients with diabetes and heart disease $2796 $2088 $1503 $1002
Patients with diabetes and hypertension $1703 $1260 $897 $588
Patients with diabetes $1205 $869 $601 $378
Table 3. Costs for patients with diabetes and other diseases.
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examined corresponds to the entire sick population. They simulated that the same target 
population is managed under the same strategies of medical purpose. The current strategy 
is defined in order to reproduce the actual pattern of healthcare resource consumption and 
related costs for COPD management.
Toy et al. [28] had examined in their study the adherence level among patients with inhaled 
COPD medications. They used the data from real-world clinical practice, as well as the national 
healthcare database. As a conclusion, it was emphasized that a correct management of COPD can 
be aided by the frequency which the patient is using the drug. Drugs with fewer daily doses are 
associated with improved adherence, and as well with lower healthcare resource use and cost. For 
1000 COPD patients, a 5% increase in proportion of days covered (PDC) reduced the annual num-
ber of inpatient visits with 2.5% and emergency room visits with 1.8%, with a slightly increased 
outpatient visits (+0.2%) and a net reduction in annual cost of approximately $300,000. This study 
suggests that dosing frequency should be an important method in increasing adherence of COPD 
patients because patients with once-daily dosing frequency had highest adherence levels relative 
to patients with twice-daily, three times daily and four times daily dosing frequency.
Simoni-Wastila et al. [25] used administrative data with COPD patients, medication continuity 
and proportion of days covered (PDC) for assessing adherence. COPD patients with higher 
adherence to prescribed treatments experienced fewer hospitalizations and lower medicare 
costs than those who presented lower adherence behaviors. Both lack of interruption in drug 
dispensing and higher adherence were associated with better clinical outcomes.
3.4. Heart diseases
The costs for heart diseases are creating a burden on the patients’ finances. Most commonly 
they experience acute myocardial infarction, known as heart attack. The costs include ambu-
lance rides, diagnostic test, hospital stays, and also surgery if needed. Employees suffering 
from heart disease require additional days off, so they are less productive at work, so it is not 
cost-effective for the economy. Additionally, the premature deaths caused by heart diseases 
are growing in the United States. In 2010, according to George and Hong [26], $41.7 billion 
was lost in potential productivity due to cardiovascular diseases.
To lower the high costs of this condition, patients must make small changes in their lifestyle. 
These preventive changes include weight lost, exercising, avoiding smoking, eating healthy, 
also they can monitor their blood pressure and cholesterol levels every month, for lowering 
the rate of mortality.
Sokol et al. [2] demonstrated that hospitalization risk for people with hypertension mono-
tonically decreased as adherence to drug treatment increased. Differences were significantly 
higher than the outcome for adherence >80% in the case of low adherence (<60%). We observe 
higher costs only for adherence in the interval [20].
In the case of congenitive heart failure, the differences in costs were not so obvious like in the case 
of hypertension. The total costs are the highest in the case of adherent patients (adherence level 
>80%). Hospitalization risk is significant higher than the outcome for adherent patients with con-
genitive heart failure in the case of patients with adherence in the interval (Tables 4 and 5) [20].
Financial Management from an Emerging Market Perspective310
Similarly, for hypertensive patients, the total costs are the smallest even if the drug cost is 
higher. These values reflect the impact of related conditions like, for example, renal disease.
Levine et al. [29] estimated for cardiology patients in USA that 125,000 deaths per year lead to 
a societal cost of 20 million lost work days and $1.5 billion lost earnings.
McCombs et al. [30] used individual patient inpatient and outpatient claims data to identify 
increased health service costs associated with interruptions in therapy. The medicines costs 
were lower with $281, but the healthcare costs were higher with $873 ($637 due to increased 
hospitalization).
3.5. Barriers to chronic disease treatment and management
Morbidity from nonadherence to medications is a major public health problem in many thera-
peutic areas [31]. About one in four people do not adhere well to prescribe drug therapy. Poor 
adherence is considered a critical barrier to treatment success and remains one of the challenges to 
healthcare professionals [32]. Combining adherence to drug therapy with adherence to other inter-
ventions limits the ability to examine the relation between adherence to drug therapy and health 
outcomes. The effect of adherence should be measured on an objective health outcome, such as 
mortality. Individual studies have reported that good adherence was associated with a lower risk 
of mortality. The association between adherence to harmful therapy and mortality is a very impor-
tant subject in the light of recent issues of the safety of patients and postmarket drug surveillance.
Adherence level Medical cost ($) Drug cost ($) Total cost ($) Hospitalization risk 
(%)
1–19 4847 31 4878 28
20–39 5973 89 6062 24
40–59 5113 184 5297 24
60–79 4977 285 5262 20
80–100 4383 489 4871 19
Table 4. Healthcare costs and hospitalization risk at different levels of adherence for patients with hypertension.
Adherence level Medical cost ($) Drug cost ($) Total cost ($) Hospitalization risk 
(%)
1–19 9826 15 9841 58
20–39 7643 90 7733 63
40–59 11244 134 11378 65
60–79 13766 158 13924 64
80–100 12261 437 12698 57
Table 5. Healthcare costs and hospitalization risk at different levels of adherence for patients with congenitive heart 
failure.
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The correlations between the mortality/morbidity rates for most chronic diseases are shown 
in Table 6.
Most nonadherence is intentional. Patients make the decision to not take their medicines 
based on some reasons:
• Fear: Patients may be scared of potential side effects or side effects they had previously 
with the same or similar medication.
• Cost: The prices of medicine can be a barrier to adherence.
• Misunderstanding: Patients do not understand the need for medicine, the side effects or the 
expected time it will take to see some results.
• Too many medications: The greater the number of different medicines prescribed and the 
higher the dosing frequency, the more likely a patient is nonadherent.
• Lack of symptoms: Patients who do not feel any differences when they start or stop to take 
their medicines may see no reason to take it.
• Worry: Concerns about becoming dependent on a medicine leads to nonadherence.
• Depression: Patients who are depressed are less likely to take their medications as 
prescribed.
• Mistrust: Patients may be suspicious of their doctor’s motives for prescribing certain medi-
cations, for example because of the marketing efforts of pharmaceutical companies to influ-
ence some prescribing patterns.
The costs of new drugs often exceed the costs of existing drugs. Such increased costs can be 
compensated by savings in other areas of health system (costs-offsets). For example, a new 
drug has fewer side effects and fewer costs to cure them. But, the first step is the patient to be 
adherent and to respect the prescription.
We cannot say that nonadherence always leads to financial losses. Nonadherence is not 
always bad for the patient. Nonadherence is protective if the prescription is inappropri-
ate or has adverse reactions. It is not useful to pay for an inefficient drug. New undesired 
costs will appear if side effects occur. Savings associated with undercompliance with over-
prescribed medications are positive economic effects. We must highlight the fact that the 
doctor, the pharmacist and the patient carry mutual responsibility for the outcome of the 
treatment. Further work is needed to develop optimal adherence patterns for individual 
patients and treatments. Important policy decisions need to be made about increasing 
nonadherence.
Physicians play a key role in medication adherence. Trust and communication are two ele-
ments critical in optimizing adherence. Various studies have shown that physicians trust is 
more important than treatment satisfaction in predicting adherence to prescribed therapy. 
In consequence, physicians trust correlates positively with the acceptance of new medi-
cation, and improves the self-reported health status. A recent meta-analysis of physician 
communication and patient adherence to treatment found that there is a 19% higher risk of 
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nonadherence among patients whose physician communicates poorly than among patients 
whose physician communicates well [34].
Healthcare providers play an unique role in assisting patients to carry out healthy behaviors 
and also to change patient’s beliefs about the risks and benefits of new medication. Another 
factor is concordance, in which patients and their providers (and physicians) agree whether 





Rheumatic heart disease, hypertensive heart disease, ischemic heart disease, 
cerebrovascular disease, inflammatory heart disease
49.90 21.23
Malignant neoplasms
Mouth and oropharynx cancers; esophagus cancer; stomach cancer; colon and rectum 
cancers; liver cancer; pancreas cancer; trachea, bronchus, lung cancers; melanoma and 
other skin cancers; breast cancer, cervix uteri cancer; corpus uteri cancer; ovary cancer; 
prostate cancer; bladder cancer; lymphomas; multiple myeloma; leukemia
21.23 10.83
Respiratory diseases
Chronic obstructive pulmonary disease, asthma 11.04 7.90
Digestive diseases
Peptic ulcer disease, cirrhosis of the liver, appendicitis 5.87 6.66
Neuropsychiatric conditions
Unipolar depressive disorders, bipolar disorder, schizophrenia, epilepsy, alcohol use 
disorders, Alzheimer’s and other dementias, Parkinson disease, multiple sclerosis, drug 
use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic 
disorder, insomnia, migraine, lead-caused mental retardation
3.32 27.70
Diabetes mellitus 2.95 2.32
Genitourinary diseases
Nephritis and nephrosis, benign prostatic hypertrophy 2.53 2.18
Endocrine disorders 0.72 1.14
Other neoplasms 0.44 0.25
Musculoskeletal diseases
Rheumatoid arthritis, osteoarthritis, gout, low back pain 0.32 4.32
Skin diseases 0.21 0.54
Congenital anomalies
Abdominal wall defect, anencephaly, anorectal atresia, cleft lip, cleft palate, esophageal 
atresia, renal agenesis, Down syndrome, congenital heart anomalies, spina bifida
0.15 3.92
Sense organ diseases
Glaucoma, cataracts, age-related vision disorders, adult-onset hearing loss 0.01 9.94
Oral conditions
Dental caries, periodontal disease, edentulism 0.01 1.06
Table 6. Morbidity and mortality rates for chronic diseases [33].
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and how a medication should be taken. Adherence requires the patient to believe there is a 
benefit to the medicine being prescribed and agree with the instructions on how to take it. 
Building trust and developing skills for successful communication between the patients and 
their provider, demands time, effort, knowledge, and practice.
Even those patients who fill and refill their prescriptions appropriately may have lapses in the 
continuity of their doses. One in five patients who receives a prescription medication cannot 
read the label.
Elliot et al. [35] concluded there is not possible to make definitive conclusions about the cost-
effectiveness of Adherence-Enhancing Interventions (AEIs) due to the heterogeneity of the 
reported studies: unclear reported adherence and outcomes, poorer quality of costs data, and 
omitted some cost elements.
4. Conclusions
The assessment of pharmaceutical drugs and healthcare programs has been in recent years 
expanded beyond efficacy and safety to cover economic implications and other conse-
quences. The incorporation of an economic perspective into the decision making process 
as to which therapies will be reimbursed by the national healthcare system and not only 
that, has made the subject of debate and discussion. National programs combining patient 
education with behavioral intervention strategies could decrease the financial losses due to 
poor adherence. The intention of this chapter was to highlight a very important problem 
of adherence in direct symbiosis with the economic situation. To ascertain the true extent 
of financial losses due to low adherence in emerging countries, more studies are urgently 
required. The absence of national policies grows the financial losses due to poor adherence. 
The answer, in our opinion, is not to spend more money on drugs and expensive treatment 
costs, but to work towards the patient in general. As individuals we are constantly making 
choices as to how we use our time and money, but we do not always think about our well-
being regarding the health.
Author details
Adina Turcu-Stiolica1*, Mihaela-Simona Subtirelu1, Adriana-Elena Taerel2, Anamaria Boboia3 
and Anca Berbecaru-Iovan1
*Address all correspondence to: adina.turcu@gmail.com
1 University of Medicine and Pharmacy of Craiova, Craiova, Romania
2 University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
3 University of Medicine and Medicine Iuliu Hatieganu, Cluj-Napoca, Romania
Financial Management from an Emerging Market Perspective314
References
[1] DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quanti-
tative review of 50 years of research. Medical Care. 2004;42:200-209
[2] Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence 
on hospitalization risk and healthcare cost. Medical Care. 2005;43(6):521-530
[3] Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treat-
ment: a meta-analysis. Medical Care. 2009;47(8):826-834
[4] The Oxford English Dictionary. Adherence. OED Online. 2nd ed. Oxford: Oxford 
University Press; 1989. Available from: http://dictionary.oed.com/cgi/entry/50002621. 
[Accessed October 14 2005]
[5] Charavel M, Bremond A, Moumjid-Ferdjaoui N, Mignotte H, Carrere MO. Shared deci-
sion-making in question. Psycho-Oncology. 2001;10:93-102
[6] Horne R, Weinman J, Barber N, Elliott R. Concordance, adherence and compliance in 
medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery 
and Organization R&D (NCCSDO); December 2005
[7] Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new medi-
cation for chronic conditions. Quality and Safety in Health Care. 2004;13:172-5
[8] Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medi-
cine. 2005;353:487-97
[9] Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 
Published by World Health Organization (2003) ISBN 10: 9241545992 ISBN 13: 9789241 
545990
[10] Mills E, Nachega J, Bangsberg D, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill C, 
Cooper C. Adherence to HAART: A systematic review of developed and developing 
nation patient-reported barriers and facilitators. PLoS Medicine. 2006;3(11):e438
[11] WHO Regional Office for Europe. Methodological Approaches for Cost-effectiveness 
and Cost-utility Analysis of Injury Prevention Measures. Europe: WHO, 2003
[12] Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. 
Annals of Medicine 2001;33:337-343
[13] Hunt SM, McKewan J, McKenna SP. Measuring health status: A new tool for clini-
cians and epidemiologists. The Journal of the Royal College of General Practitioners. 
1985;35:185-188
[14] Kaplan RM, Anderson JP. The general health policy model: An integrated approach. 
In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. 
Philadelphia: Lippincott-Raven; 1996. pp. 309-322
Analysis of Financial Losses due to Poor Adherence of Patients with Chronic Diseases and Their...
http://dx.doi.org/10.5772/intechopen.70320
315
[15] Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development 
and final revisions of a health status measure. Medical Care. 1976;14:57-67
[16] Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI®) sys-
tem for assessing health-related quality of life in clinical studies. Annals of Medicines. 
2001;33:375-384
[17] Berry D, Bradlow A, Bersellini E. Perceptions of the risks and benefits of medicines in 
patients with rheumatoid arthritis and other painful musculoskeletal conditions. 
Rheumatology. 2004;43:901-905
[18] McElhone K, Teh L-S, Walker J, Abbott J. Treatment adherence in systemic lupus erythe-
matosus (SLE). Rheumatology. 2005;44(Suppl.):i141
[19] Neame R, Hammond A. Beliefs about medications: A questionnaire survey of people 
with rheumatoid arthritis. Rheumatology. 2005;44:762-767
[20] Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. 
Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. Journal 
of Rheumatology. 2003;30:44-54
[21] Kerr EA, Gerzoff RB, Krein SL, et al. Diabetes care quality in the Veterans Affairs Health 
Care System and commercial managed care: The TRIAD study. Annals of Internal 
Medicine. 2004;141:272-281
[22] American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes 
Care. 2007;30:S4-S41
[23] Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence 
and associated health care costs in an older population with type 2 diabetes mellitus: A 
longitudinal cohort study. Clinical Therapeutics. 2003;25:2958-2971
[24] Gilmer TP, O’Connor PJ, Manning WG, Rush WA. The cost to health plans of poor gly-
cemic control. Diabetes Care. 1997;20(12):1847-1853
[25] Simoni-Wastila L, Wei YJ, Qian J, Zuckerman I, Stuart B, Shaffer T, Dalal A, Bryant-
Comstock L. Association of Chronic Obstructive Pulmonary Disease maintenance 
medication adherence with all-cause hospitalization and spending in a population. The 
American Journal of Geriatric Pharmacotherapy. 2012;10(3):201-210
[26] George M., & Hong, Y. Aspirin therapy for primary prevention of cardiovascular dis-
ease. National Business Group on Health, April 2011
[27] Zaniolo O, Bettoncelli G, Bosio G, et al. Ricerca assistenza e programmazione: dall’audit 
clinic al modello di impatto sul budget nella BPCO. Farmacoeconomia e percorsi tera-
peutici. 2010;11:121-135
[28] Toy EL, Beaulieu NU, et al. Treatment of COPD: Relationships between daily dosing 
frequency, adherence, resource use, and costs. Respiratory Medicine. 2011;105:435-411
Financial Management from an Emerging Market Perspective316
[29] Levine DM. Improving patient compliance. Paper presented at the 33rd Pharmacy Con-
ference. Rutgers University; 1984
[30] McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihyper-
tensive drug therapy in a Medicaid population. Medical Care. 1994;32(3):214-226
[31] Lewis A. Noncompliance: A $100 billion problem. Remington Rep. 1997;5(4):14-15
[32] Simpson SH, Eurich DT, et al. A meta-analysis of the association between adher-
ence to drug therapy and mortality. British Medical Journal. 2006. DOI: 10.1136/bmj. 
38875.675486.55
[33] Stuckler D. World Health Report 2004 and Global Burden of Disease Statistics, World 
Health Organization. Population causes and consequences of leading chronic diseases: 
A comparative analysis of prevailing explanations. Milbank Quarterly. 2008;86(2):273-
326. DOI: 10.1111/j.1468-0009.2008.00522.x
[34] Haskard Zolnierek KB, DiMatteo. Physician communication and patient adherence to 
treatment: A meta-analysis. Medical Care. 2009;47(8):826-834
[35] Elliot RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: 
A quality assessment of the evidence. Annals of Pharmacotherapy. 2005;39(3):508-515
[36] Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy 
conversion to a biphasic insulin analog pen among privately insured patients with type 
2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
Analysis of Financial Losses due to Poor Adherence of Patients with Chronic Diseases and Their...
http://dx.doi.org/10.5772/intechopen.70320
317

